Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities

Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.